Sotagliflozin: clinical trials recruiting now
3
Recruiting trials
9
Conditions studied
11
US states with sites
4
Countries
FDA drug label
- FDA-approved
- Yes. Sotagliflozin appears in the FDA drug-label database. Marketed as INPEFA.
- Drug class
- Sodium-Glucose Cotransporter 2 Inhibitor (FDA established pharmacologic class)
- Mechanism of action
- Sodium-Glucose Transporter 2 Inhibitors; P-Glycoprotein Inhibitors (as stated on the FDA label)
FDA-approved use
INPEFA is indicated to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with: heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors INPEFA is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with: heart failure ( 1 ) or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors ( 1 )
Phase breakdown
Phase 2 1
Phase 3 2
Conditions being studied
Recruiting trials involving Sotagliflozin
- Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes
- Sotagliflozin in Patients With Heart Failure Symptoms and Type 1 Diabetes
- Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease
Common questions
Is Sotagliflozin FDA-approved?
Yes, marketed as INPEFA.
How many recruiting trials involve Sotagliflozin?
3 recruiting trials across 9 conditions.
Is this list of trials complete?
No. For the full record, search ClinicalTrials.gov.